In addition to the nitrogen-based heterocycles presented so far, a number of others nitrogen-based scaffolds have also been reported as promising agents for GBM treatment, including pyrazolo-triazole, imidazotetrazine, piperidine, purine, imidazopyrazine, pyrazole, triazole among others.
With four imidazopyridine-containing drugs and one pyrazolopyridine-containing drug on the market, bicyclic pyridines containing ring-junction nitrogen are privileged structures in medicinal chemistry. With two nitrogen atoms with potential to serve as hydrogen bond acceptors, imidazopyridines and pyrazolopyridines may boost binding to target proteins and elevate potency. In addition, these structures have found utility in FBDD, covalent inhibitors, reducing metabolic liabilities, and creating novel chemical space and intellectual properties. With many of the advanced intermediates now commercially available, they will find more and more applications in drug discovery.
Buscar 
+86 21 5895 0110 
